How can we, humans, look at our relationship to nature differently? In season three of Going Wild, on top of stories about animals, we invite you to journey through the entire ecological web — from the tiniest of life forms to apex predators — alongside the scientists, activists and adventurers who study it. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals in their natural habitats all over the world for years. Our award-winning podcast takes you inside the hidde ...
…
continue reading
Contenuto fornito da Sano Genetics. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Sano Genetics o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !
Vai offline con l'app Player FM !
EP 118: The role of genetics in drug discovery and development with Dr. Matt Nelson
Manage episode 396148472 series 2631947
Contenuto fornito da Sano Genetics. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Sano Genetics o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Summary:
0:00 Introduction
5:45 Lessons learned from 15 years at GSK: How has genetics and drug discovery evolved over time?
8:10 Matt’s seminal 2015 paper: Quantifying the impact of human genetic evidence on the probability of success in drug development
11:40 Which types of genetic evidence are the best drivers of success in clinical trials?
13:30 Matt’s 2023 paper ‘Refining the Impact of Genetic Evidence on Clinical Success’
18:15 Comparing the value of scale in patient-reported data and genotype arrays (e.g. 23andMe) to deep clinical phenotypes and exomes (e.g. UKBiobank)
23:00 The next leaps forward in newborn and population screening
23:50 Targeting genetic subtypes in drug development
26:15 The role of polygenic risk scores in drug development and the early proof of concept studies
28:15 Proactive trial design to exclude participants who might experience safety risks
30:20 Gene editing technologies for rare Mendelian diseases and Verve Therapeutics approach to treating familial hypercholesterolemia
33:40 Looking forward: The role of drug development in preventing disease
35:50 Matt’s transition from GSK to Deerfield and GenScience
38:00 How the role of genetics and genomics in healthcare investment has changed over the past 10 years
39:00 Genscience’s vision to use genomic data for drug discovery and decision-making
43:25 Looking forward: Linking genetic data to electronic health records in the US and Europe
47:50 Closing Remarks
187 episodi
Manage episode 396148472 series 2631947
Contenuto fornito da Sano Genetics. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Sano Genetics o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Summary:
0:00 Introduction
5:45 Lessons learned from 15 years at GSK: How has genetics and drug discovery evolved over time?
8:10 Matt’s seminal 2015 paper: Quantifying the impact of human genetic evidence on the probability of success in drug development
11:40 Which types of genetic evidence are the best drivers of success in clinical trials?
13:30 Matt’s 2023 paper ‘Refining the Impact of Genetic Evidence on Clinical Success’
18:15 Comparing the value of scale in patient-reported data and genotype arrays (e.g. 23andMe) to deep clinical phenotypes and exomes (e.g. UKBiobank)
23:00 The next leaps forward in newborn and population screening
23:50 Targeting genetic subtypes in drug development
26:15 The role of polygenic risk scores in drug development and the early proof of concept studies
28:15 Proactive trial design to exclude participants who might experience safety risks
30:20 Gene editing technologies for rare Mendelian diseases and Verve Therapeutics approach to treating familial hypercholesterolemia
33:40 Looking forward: The role of drug development in preventing disease
35:50 Matt’s transition from GSK to Deerfield and GenScience
38:00 How the role of genetics and genomics in healthcare investment has changed over the past 10 years
39:00 Genscience’s vision to use genomic data for drug discovery and decision-making
43:25 Looking forward: Linking genetic data to electronic health records in the US and Europe
47:50 Closing Remarks
187 episodi
Όλα τα επεισόδια
×Benvenuto su Player FM!
Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.